• In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.
  Rajoli RKR, Back DJ, Rannard S,  et al  Clin Pharmacokinet. 2017 May  24
• Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
  Markowitz M, Frank I, Grant RM, et al .
  Lancet HIV. 2017 May 22
  Abstract
• Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women.
  Trezza C, Ford SL, Gould E, et alBr J Clin Pharmacol. 2017 Jan 14.
• FULL-TEXT ARTICLE
  Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date.
  Whitfield T, Torkington A, van Halsema C.
  HIV AIDS (Auckl). 2016 Oct 14;8:157-164.
  Paper
• FULL-TEXT ARTICLE
  Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
  Margolis DA, Brinson CC, Smith GH,  et al
  Lancet Infect Dis. 2015 Oct;15(10):1145-55
  Paper
• Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.
  Reese MJ, Bowers GD, Humphreys JE,  et al
  Xenobiotica. 2015 Sep 4:1-12.
  Abstract
• Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
  Margolis DA, Brinson CC, Smith GH,  et al
  Lancet Infect Dis. 2015 Jul 17
  Abstract
• Cabotegravir long-acting for HIV-1 prevention.
  Andrews CD, Heneine W.
  Curr Opin HIV AIDS. 2015 Jul;10(4):258-63.
  Abstract
• Formulation and pharmacology of long-acting cabotegravir.
  Trezza C, Ford SL, Spreen W,  et al
  Curr Opin HIV AIDS. 2015 Jul;10(4):239-45.
  Abstract
• Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans.
  Bowers GD, Culp A, Reese MJ, Tabolt G,
  Xenobiotica. 2015 Jul 1:1-16
  Abstract
• GSK1265744 Pharmacokinetics in Plasma and Tissue Following Single-Dose Long-Acting (LA) Injectable Administration in Healthy Subjects.
  Spreen W, Ford SL, Chen S,  et al
  J Acquir Immune Defic Syndr. 2014 Aug 19
  Abstract
• Parenteral patent drug S/GSK1265744 has the potential to be an effective agent in pre-exposure prophylaxis against HIV infection.
  Taha H, Morgan J, Das A, Das S.
  Recent Pat Antiinfect Drug Discov. 2013 Dec;8(3):213-8.
  Abstract
• Effects of Etravirine on the Pharmacokinetics of the Integrase Inhibitor S/GSK1265744.
  Ford SL, Gould E, Chen S, et al 
  Antimicrob Agents Chemother. 2012 Oct 31.
  Abstract
• Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.
  Andrews CD, Spreen WR, Mohri H,  et al
  Science. 2014 Mar 7;343(6175):1151-4.
  Abstract
  Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor.
  Spreen W, Min S, Ford SL, et al
  HIV Clin Trials. 2013 Sep-Oct;14(5):192-203
  Abstract
• FULL-TEXT ARTICLE
  Long-acting injectable antiretrovirals for HIV treatment and prevention.
  Spreen WR, Margolis DA, Pottage JC Jr.
  Curr Opin HIV AIDS. 2013 Nov;8(6):565-71
  Paper
• FULL-TEXT ARTICLE
  Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
  Ford SL, Gould E, Chen S,  et al
  Antimicrob Agents Chemother. 2013 Nov;57(11):5472-7
  Paper
• Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744).
  Johns BA, Kawasuji T, Weatherhead JG, et al
  J Med Chem. 2013 Jul 25;56(14):5901-16
  Abstract
• FULL-TEXT ARTICLE
  Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK1265744.
  Ford SL, Gould E, Chen S,  et al
  Antimicrob Agents Chemother. 2013 Jan;57(1):277-80.
  Paper
   

Cabotegravir (GSK-1265744)